TokenPost·
Lexeo Trial Data Leads Raymond James and Cantor Fitzgerald to Raise Targets

The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.
Every crypto headline. One feed. Updated every minute.

The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.